1. Pink Sheet

Multiple Coronavirus Vaccines Is Policy Aim, But Will Complicate Supply Chain

 
• By Derrick Gingery

At Senate hearing, FDA and NIH officials say government and vaccine developers are outlining production needs with ability to shift manufacturing from their candidates to others to ensure production of the most promising products. FDA Commissioner Hahn says as an essential worker he would break quarantine if needed at a critical White House or other meeting.

Senators and staffers practice social distancing and wear masks during HELP's coronavirus hearing on 12 May 2020
Senators and staffers practice social distancing and wear masks during HELP's coronavirus hearing on 12 May 2020. • Source: Screenshot of Senate webcast

US Food and Drug Administration Commissioner Stephen Hahn reiterated the federal government’s intent in helping develop multiple coronavirus vaccines, even though it may create challenges for the supply chain.

Hahn said during a 12 May Senate Health, Education, Labor and Pensions Committee hearing that the agency is committed to ensuring syringes, needles and other supplies will be available once a vaccine is developed

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.